GSK (GSK) RNS Announcements

Add to Alert list
Date Time Source Announcement
13 Nov 2023 07:00 AM
RNS
GSK receives positive CHMP opinion for momelotinib
01 Nov 2023 03:00 PM
RNS
Total Voting Rights
01 Nov 2023 07:00 AM
RNS
3rd Quarter Results
30 Oct 2023 07:00 AM
RNS
Jemperli trial meets overall survival endpoint
26 Oct 2023 07:00 AM
RNS
NMPA approves Vocabria+Rekambys in China
25 Oct 2023 03:30 PM
RNS
Director/PDMR Shareholding
25 Oct 2023 07:00 AM
RNS
New data for Arexvy, GSK’s RSV vaccine
20 Oct 2023 03:30 PM
RNS
Director/PDMR Shareholding
18 Oct 2023 03:30 PM
RNS
Director/PDMR Shareholding
17 Oct 2023 03:30 PM
RNS
Director/PDMR Shareholding
16 Oct 2023 07:00 AM
RNS
Jemperli plus chemotherapy positive CHMP opinion
13 Oct 2023 03:30 PM
RNS
Director/PDMR Shareholding
12 Oct 2023 03:30 PM
RNS
Director/PDMR Shareholding
11 Oct 2023 07:00 AM
RNS
Zantac (ranitidine) litigation
10 Oct 2023 11:00 AM
RNS
Holding(s) in Company
09 Oct 2023 07:00 AM
RNS
GSK and Zhifei announce vaccine partnership
06 Oct 2023 07:00 AM
RNS
GSK completes sale of shares in Haleon plc
05 Oct 2023 04:46 PM
RNS
GSK announces intention to sell shares in Haleon
02 Oct 2023 03:00 PM
RNS
Total Voting Rights
27 Sep 2023 03:00 PM
RNS
Directorate Change
25 Sep 2023 07:00 AM
RNS
GSK RSV vaccine for older adults approved in Japan
21 Sep 2023 03:30 PM
RNS
Director/PDMR Shareholding
19 Sep 2023 07:00 AM
RNS
Apretude for PrEP receives EMA approval
18 Sep 2023 07:00 AM
RNS
FDA approves Ojjaara (momelotinib)
13 Sep 2023 03:30 PM
RNS
Director/PDMR Shareholding
11 Sep 2023 03:30 PM
RNS
Director/PDMR Shareholding
11 Sep 2023 07:00 AM
RNS
Momelotinib filing accepted in Japan
06 Sep 2023 03:30 PM
RNS
Director/PDMR Shareholding
01 Sep 2023 03:00 PM
RNS
Total Voting Rights
01 Sep 2023 07:00 AM
RNS
GSK’s Nucala CRSwNP submission accepted in Japan
31 Aug 2023 03:16 PM
RNS
Holding(s) in Company
31 Aug 2023 03:14 PM
RNS
Holding(s) in Company
25 Aug 2023 03:30 PM
RNS
Director/PDMR Shareholding
23 Aug 2023 03:30 PM
RNS
Director/PDMR Shareholding
23 Aug 2023 07:00 AM
RNS
Shingrix data demonstrate 100% efficacy in China
22 Aug 2023 03:30 PM
RNS
Director/PDMR Shareholding
10 Aug 2023 03:30 PM
RNS
Director/PDMR Shareholding
09 Aug 2023 03:30 PM
RNS
Director/PDMR Shareholding
01 Aug 2023 03:00 PM
RNS
Total Voting Rights
31 Jul 2023 06:00 PM
RNS
FDA approves new use for Jemperli plus chemo
31 Jul 2023 03:30 PM
RNS
Director/PDMR Shareholding
28 Jul 2023 03:30 PM
RNS
Director/PDMR Shareholding
26 Jul 2023 07:00 AM
RNS
2nd Quarter Results
24 Jul 2023 07:00 AM
RNS
Cabotegravir LA for PrEP receives positive CHMP
20 Jul 2023 03:30 PM
RNS
Director/PDMR Shareholding
17 Jul 2023 03:30 PM
RNS
Director/PDMR Shareholding
13 Jul 2023 03:30 PM
RNS
Director/PDMR Shareholding
03 Jul 2023 03:00 PM
RNS
Total Voting Rights
28 Jun 2023 03:43 PM
RNS
GSK completes acquisition of BELLUS Health
27 Jun 2023 07:00 AM
RNS
FDA Fast Track for Gonorrhoea Vaccine Candidate

GSK PLC, known as GSK, is a renowned multinational pharmaceutical and biotechnology company with its global headquarters in London. Traded as GSK on the London Stock Exchange (LSE), it has a rich history that traces back to the establishment of Plough Court Pharmacy in London in 1715. Over the centuries, GSK has grown from a handful of individual founders into a company of over 69,000 people.

The company's journey includes the development of 15 first-in-class or combination vaccines and pioneering medications in respiratory, antibiotics, antivirals, and oncology. GSK has been a leader in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

In 2000, Glaxo Wellcome and SmithKline Beecham merged to form the modern GSK, becoming a key player on the LSEG. Today, GSK continues to shape the global healthcare landscape, committed to defeating diseases that impact people's health. This evergreen company remains at the forefront of the pharmaceutical industry, embodying its founding principle of improving the quality of human life by enabling people to do more, feel better, and live longer.

UK 100

Latest directors dealings